De Novo and Secondary Myelodysplastic Syndrome

Current Clinical Trials

Standard treatment options:

• Myeloablative allogeneic stem cell transplantation.
• Erythropoeitic growth factors, in patients with endogenous erythropoietin levels less than 500 u/mL.
• 5-azacitidine or decitabine.
• Lenalidomide for patients with deletions of chromosome 5q31.
• Antithymocyte globulin.

Treatment options under clinical evaluation:

• Nonmyeloablative stem cell transplantation.
• Farnesyl transferase inhibitors (tipifarnib and lonafarnib).
• Combination regimens.
• Thrombopoietic agents.

Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with de novo myelodysplastic syndromes ¹ and secondary myelodysplastic syndromes ². The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.

General information about clinical trials is also available from the NCI Web site ³.